HealthDay: Is new clot-busting medication better treatment for stroke?
February 3, 2022
HealthDay featured University of Cincinnati's Dr. Joseph Broderick in an article discussing a new clot-busting drug that may be safer when treating strokes.
February 3, 2022
HealthDay featured University of Cincinnati's Dr. Joseph Broderick in an article discussing a new clot-busting drug that may be safer when treating strokes.
October 14, 2021
UC's Dr. Rhonna Shatz is featured in a Well + Good article exploring certain brain functions that can sometimes improve as we age.
March 17, 2022
MSN featured University of Cincinnati research led by Alberto Espay and Luca Marsili that is expanding genetic testing of rare movement disorders for Chilean patients.
January 31, 2022
55KRC's Simply Medicine program highlighted the University of Cincinnati's Dr. Joseph Broderick and the FASTEST stroke clinical trial.
November 8, 2022
The University of Cincinnati's Stacie Demel, DO, PhD, joined the Simply Medicine podcast to discuss TNK, a new treatment for acute ischemic stroke now available to patients across Greater Cincinnati.
November 3, 2022
The University of Cincinnati's Rhonna Shatz was featured in a U.S. News and World Report article on signs that a patient with dementia may need a higher level of care.
May 18, 2022
The University of Cincinnati's Eva Mistry and Pooja Khatri were recent guests on local news programs to discuss National Stroke Awareness Month.
July 25, 2022
The University of Cincinnati's Hyacinth I. Hyacinth was a guest on 55KRC's Simply Medicine program to discuss his research into sickle cell disease, stroke and cognitive impairment.
August 11, 2022
The University of Cincinnati's Joseph Broderick, MD, provided comments in a TCTMD article reviewing the results of a recent study that found administering the drug tirofiban before endovascular thrombectomy does not improve functional outcomes in patients.
September 28, 2022
The University of Cincinnati's Alberto Espay, MD, was featured in an NBC News article reporting on results from a phase three Alzheimer's drug trial.